Total number of shares and voting rights in Zealand Pharma at June 30, 2022
2022年6月30日 - 10:44PM
Company announcement – No. 30 /
2022
Total number of shares and voting
rights in Zealand Pharma
at June
30,
2022
Copenhagen, DK and Boston, MA, June 30, 2022 –
Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50
78), a Copenhagen-based biotechnology company focused on the
discovery and development of innovative peptide-based medicines, in
accordance with section 32 of the Danish Capital Markets Act,
announces the total number of shares and voting rights in the
Company at the end of a calendar month during which there have been
changes to its share capital.
In Company announcement No. 26/2022 from June 3,
2022, Zealand announced an increase in share capital relating to a
private placement. Following this announcement, the table below
lists the total number of shares and voting rights in Zealand up to
and including June 30, 2022.
Date |
Number of
shares(nominal
value of DKK 1 each) |
Share capital(nominal value in
DKK) |
Number of voting rights |
June 30, 2022 |
46,526,510 |
46,526,510 |
46,526,510 |
# # #
About Zealand Pharma A/SZealand Pharma A/S
(Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on
the discovery and development of peptide-based medicines. More than
10 drug candidates invented by Zealand have advanced into clinical
development, of which two have reached the market and three
candidates are in late-stage development. In addition, license
collaborations with Boehringer Ingelheim and AstraZeneca create
opportunities for more patients to potentially benefit from
Zealand-invented peptide investigational agents currently in
development.
Zealand was founded in 1998 and headquartered in Copenhagen,
Denmark, with a presence in the U.S. that includes Boston. For more
information about Zealand’s business and activities, please
visit http://www.zealandpharma.com.
Forward-Looking StatementThe above information
contains forward-looking statements that provide Zealand Pharma’s
expectations or forecasts of future events. Such forward-looking
statements are subject to risks, uncertainties and inaccurate
assumptions, which may cause actual results to differ materially
from expectations set forth herein and may cause any or all of such
forward-looking statements to be incorrect. If any or all of such
forward-looking statements prove to be incorrect, our actual
results could differ materially and adversely from those
anticipated or implied by such statements. All such forward-looking
statements speak only as of the date of this release and are based
on information available to Zealand Pharma as of the date of this
release.
For further information, please contact:
Zealand
Pharma Investor Relations |
Maeve
Conneighton |
Argot Partners |
investors@zealandpharma.com |
|
Zealand
Pharma Media Relations |
David Rosen |
Argot Partners |
media@zealandpharma.com |
Zealand Pharma AS (NASDAQ:ZEAL)
過去 株価チャート
から 5 2024 まで 6 2024
Zealand Pharma AS (NASDAQ:ZEAL)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Zealand Pharma AS (ナスダック市場): 0 recent articles
その他のニュース記事